About this item:

40 Views | 9 Downloads

Author Notes:

Malú G. Tansey, Ph.D., Department of Physiology, Emory University School of Medicine, 605L Whitehead Biomedical Res. Bldg. 615 Michael Street, Atlanta, GA 30322-3110, malu.tansey@emory.edu, (404)727-6126 (Office).

1. Research project: A. Conception, B. Organization, C. Execution.

2. Statistical Analysis: A. Design, B. Execution, C. Review and Critique.

3. Manuscript: A. Writing of the first draft, B. Review and Critique.

M.C.H.: 1B, 1C, 2A, 2B, 2C, 3A; J.C.: 1B, 1C, 3B; S.A.F.: 1A, 1B, 1C, 3B; E.S.M.: 1A, 1B, 1C, 3B; C.P.Z.: 1A, 1B, 1C, 3B; E.M.H.: 1A, 1B, 1C, 3B; H.P.: 1A, 1B, 1C, 3B; V.S.H.: 2A, 2B, 2C, 3B; M.G.T.: 1A, 1B, 2A, 3B;

M.G.T. is a member of the Executive Scientific Advisory Board for The Michael J. Fox Foundation for Parkinson’s Research, a member of the Scientific Review Board for the Alzheimer’s Drug Discovery Foundation, and a consultant for Celgene Corporation.

Complete list of disclosures available in full text.

Subjects:

Research Funding:

Subject recruitment and characterization, stool and metadata collection, and multiplexed immunoassays were funded by NIH grants NS036960 (H.P.); NS067469 (H.P.); and P50 NS062684 (C.P.Z.).

E.S.M. is supported by the Riley Family Chair in Parkinson’s Disease.

Keywords:

  • Science & Technology
  • Life Sciences & Biomedicine
  • Clinical Neurology
  • Neurosciences & Neurology
  • inflammation
  • Parkinson's disease
  • intestine
  • stool
  • biomarker
  • INTESTINAL BACTERIAL OVERGROWTH
  • IRRITABLE-BOWEL-SYNDROME
  • ALPHA-SYNUCLEIN
  • CROHNS-DISEASE
  • GUT MICROBIOTA
  • KAPPA-B
  • TRANSIT-TIME
  • CONSTIPATION
  • SMOKING
  • RISK

Stool Immune Profiles Evince Gastrointestinal Inflammation in Parkinson's Disease

Tools:

Journal Title:

Movement Disorders

Volume:

Volume 33, Number 5

Publisher:

, Pages 793-804

Type of Work:

Article | Post-print: After Peer Review

Abstract:

Background: Gastrointestinal symptoms are common in Parkinson's disease and frequently precede the development of motor impairments. Intestinal inflammation has been proposed as a driver of disease pathology, and evaluation of inflammatory mediators in stool could possibly identify valuable early-stage biomarkers. We measured immune- and angiogenesis-related proteins in human stool to examine inflammatory profiles associated with Parkinson's disease. Methods: Stool samples and subjects' self-reported metadata were obtained from 156 individuals with Parkinson's disease and 110 without, including spouse and nonhousehold controls. Metadata were probed for disease-associated differences, and levels of 37 immune and angiogenesis factors in stool homogenates were measured by multiplexed immunoassay and compared across experimental groups. Results: Parkinson's disease patients reported greater incidence of intestinal disease and digestive problems than controls. Direct comparison of levels of stool analytes in patients and controls revealed elevated vascular endothelial growth factor receptor 1, interleukin-1α, and CXCL8 in patients' stool. Paired comparison of patients and spouses suggested higher levels of multiple factors in patients, but this was complicated by sex differences. Sex, body mass index, a history of smoking, and use of probiotics were found to strongly influence levels of stool analytes. Multivariate analysis accounting for these and other potential confounders confirmed elevated levels of interleukin-1α and CXCL8 and also revealed increased interleukin-1β and C-reactive protein in stool in Parkinson's disease. These differences were not dependent on subject age or disease duration. Conclusions: Levels of stool immune factors indicate that intestinal inflammation is present in patients with Parkinson's disease.

Copyright information:

© 2018 International Parkinson and Movement Disorder Society

Export to EndNote